Arrowhead Pharmaceuticals Inc
ARWR
Company Profile
Business description
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Contact
177 E Colorado Boulevard
Suite 700
PasadenaCA91105
USAT: +1 626 304-3400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2025
Employees
609
Stocks News & Analysis
stocks
The fight for Insignia continues
Numerous acquisition proposals vindicate Insignia's improved earnings momentum.
stocks
Trouble continues as Star Entertainment burns through cash
More pain in the horizon as the company struggles to stay afloat.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,680.50 | 27.80 | 0.32% |
| CAC 40 | 7,826.73 | 55.78 | 0.72% |
| DAX 40 | 21,258.38 | 216.38 | 1.03% |
| Dow JONES (US) | 44,025.81 | 537.98 | 1.24% |
| FTSE 100 | 8,577.62 | 29.33 | 0.34% |
| HKSE | 19,778.77 | 327.78 | -1.63% |
| NASDAQ | 19,756.78 | 126.58 | 0.64% |
| Nikkei 225 | 39,646.25 | 618.27 | 1.58% |
| NZX 50 Index | 13,037.14 | 15.76 | -0.12% |
| S&P 500 | 6,049.24 | 52.58 | 0.88% |
| S&P/ASX 200 | 8,429.80 | 27.40 | 0.33% |
| SSE Composite Index | 3,213.62 | 29.00 | -0.89% |